TABLE 1.
Clinical Characteristics and Laboratory Data of Critically Ill Patients on ICU Admission
| Characteristics | ICU COVID-19 | ICU Non-COVID-19 | p | Reference Values |
|---|---|---|---|---|
| Number of patients, n | 26 | 33 | ||
| Age (yr), median (IQR) | 62 (55–75) | 57 (43–74) | 0.2 | |
| Sex, n (%) | ||||
| Male | 19 (73.1) | 20 (60.6) | 0.3 | |
| Female | 7 (26.9) | 13 (39.4) | ||
| Comorbidities, n (%) | 18 (69.2) | 12 (36.4) | 0.01 | |
| Hypertension | 13 | 7 | ||
| Hyperlipidemia | 6 | 0 | ||
| Diabetes | 3 | 1 | ||
| Coronary artery disease | 2 | 2 | ||
| Chronic obstructive pulmonary disease | 0 | 1 | ||
| Chronic kidney disease | 0 | 1 | ||
| Acute Physiology and Chronic Health Evaluation II score, mean ± sd | 15 ± 5 | 17 ± 6 | 0.2 | |
| Pao2/Fio2 (mm Hg), median (IQR) | 178 (127–261) | 245 (189–353) | 0.003 | |
| Vitals signs | ||||
| Heart rate (beats/min), median (IQR) | 92 (82–106) | 82 (64–104) | 0.05 | |
| Mean arterial pressure (mm Hg), median (IQR) | 75 (71–86) | 75 (69–97) | 0.9 | |
| Temperature (°C), median (IQR) | 37.9 (37.4–38.2) | 37.0 (35.5–37.9) | 0.005 | |
| Laboratory data | ||||
| Hemoglobin, mean ± sd | 13.1 ± 1.8 | 10.0 ± 2.3 | <0.0001 | 12–17.5 |
| WBC count (per μL), mean ± sd | 10,480 ± 5,000 | 14,170 ± 5,850 | 0.02 | 4–10.5 × 103 |
| Neutrophils (%), mean ± sd | 81.6 ± 6.7 | 81.2 ± 6.7 | 0.8 | 40–70 |
| Lymphocytes (%), mean ± sd | 13.0 ± 6.2 | 10.1 ± 4.7 | 0.08 | 25–45 |
| Platelets (per μL), median (IQR) | 220,000 (143,000–270,000) | 163,000 (126,000–230,000) | 0.04 | 140–450 × 103 |
| Urea (mg/dL), median (IQR) | 31 (25–53) | 31 (21–37) | 0.5 | 10–50 |
| Creatinine (mg/dL), median (IQR) | 0.9 (0.7–1.2) | 0.7 (0.6–0.9) | 0.05 | 0.6–1.4 |
| Glucose (mg/dL), median (IQR) | 137 (119–187) | 122 (100–183) | 0.1 | 70–110 |
| Total bilirubin (mg/dL), median (IQR) | 0.7 (0.4–1.1) | 0.6 (0.4–1.0) | 0.5 | <1 |
| C-reactive protein (mg/dL), median (IQR) | 9.7 (4.4–20.8) | 9.9 (5.8–17.5) | 0.9 | <0.5 |
| Fibrinogen (mg/dL), mean ± sd | 631 ± 161 | 421 ± 167 | <0.0001 | 200–400 |
| Lactate dehydrogenase (U/L), median (IQR) | 465 (345–632) | 290 (206–460) | 0.001 | <225 |
| Inotropes (mean dose, µg/kg/min), median (IQR) | 0.2 (0.0–0.3) | 0.3 (0.1–0.5) | 0.2 | |
| Outcomes | ||||
| Length of stay in the ICU (d), median (IQR) | 23 (15–40) | 21 (10–31) | 0.2 | |
| Mechanical ventilation, n (%) | 21 (80.8) | 33 (100) | 0.01 | |
| Mechanical ventilation duration (d), median (IQR) | 15 (5–37) | 10 (5–23) | 0.2 | |
| ICU mortality, n (%) | 8 (30.8) | 11 (33.3) | 0.8 | |
COVID-19 = coronavirus disease 2019, IQR = interquartile range.
Data are expressed as percentages of total related variable (%) and mean ± sd for normally distributed variables and median (IQR) for skewed data.
Patients’ outcome and demographics are also shown.